Vorolanib is under clinical development by Betta Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vorolanib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vorolanib overview
Vorolanib (Fumena) is an indoline derivative. It is formulated as tablets for oral route of administration. Fumena is indicated for the treatment of advanced renal cell carcinoma.
Vorolanib (X-82) is under development for the treatment of solid tumors including epithelial ovarian adenocarcinoma, untreated advanced metastatic renal cell carcinoma, metastatic gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction, wet age-related macular degeneration, small cell lung cancer, non-small cell lung cancer, thymic carcinoma, soft tissue sarcoma, pancreatic neuroendocrine tumors, and advanced solid tumors. The drug candidate is administered orally. X-82 is a small molecule indolinone inhibitor of signaling through the growth factor receptors VEGFR and PDGFR.
It was also under development for the treatment of breast cancer, wet age-related macular degeneration, prostate cancer, gastric cancer, hepatocellular carcinoma, fallopian tube cancer, peritoneal cancer, sarcoma, metastatic mucosal melanoma, small cell lung cancer and choroidal neovascularization and myopia.
Betta Pharmaceuticals overview
Betta Pharmaceuticals is a pharmaceutical company that specializes in the research and development, manufacturing, and sales of innovative drugs. It primarily focuses on the development of new drugs, particularly in the field of oncology. Its products include Icotinib hydrochloride (Conmana), Ensartinib hydrochloride (Ensacove), Bevacizumab, and Befotertinib (Surmana), that are used for the treatment of various types of cancer. Betta Pharmaceuticals develops its pipeline with small and macromolecule products for multiple cancer treatments. These products are primarily used in the healthcare industry for the treatment of diseases such as non-small cell lung cancer (NSCLC) and metastatic colorectal cancer. The company operates research and development centers in the US, and China. Betta Pharmaceuticals is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of Vorolanib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
